Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Diarrhea 2Rectal Neoplasms 1Neoplasms 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Bevacizumab 112Fluorouracil 98Oxaliplatin 96Leucovorin 96Irinotecan 86Capecitabine 73Cetuximab 64Panitumumab 42pembrolizumab 38regorafenib 28Nivolumab 23IFL protocol 22Folfox protocol 21trifluridine tipiracil drug combination 14Radiotherapy 13durvalumab 11Gemcitabine 10Celecoxib 10tremelimumab 7binimetinib 7aflibercept 7Drug Therapy 7Disulfides 7Cyclophosphamide 7Trifluridine 6Trastuzumab 6Sunitinib 6Paclitaxel 6Immunoglobulin G 6Colonoscopy 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Colorectal Neoplasms × Calcium Aluminosilicate × Clear all
NCT00748215 2020-12-02

Calcium Aluminosilicate Anti-Diarrheal in Treating and Preventing Diarrhea in Patients With Metastatic Colorectal Cancer Receiving Irinotecan

M.D. Anderson Cancer Center

Phase 2 Completed
100 enrolled 17 charts
Gastrointestinal

Colonic Neoplasms, Diarrhea, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡